JB Chemicals & Pharmaceuticals’ (JBCPL) proposed deal to sell JBCPL's Russia-CIS prescription products business to Dr. Reddy's Laboratories (DRL) has been mutually called off in overall business interest of both parties. Accordingly, the agreements entered into between the parties including agreement between Russian subsidiaries of the company as well as DRL have been terminated.
The company has decided to aggressively pursue prescription products business in Russia- CIS countries and is in the process of restructuring the same so that it continues to remain profitable.
Earlier on July 22, 2011, JB Chemicals & Pharmaceuticals’ (JBCPL) board had granted its approval to the company for entering into a definitive agreement to sell its Russia-CIS prescription products business to Dr Reddy’s Laboratories. The transaction which involves the sale of products registration, intellectual properties etc., is for the consideration worth Rs 137.5 crore.
JBCPL is one of India’s leading pharmaceutical companies which manufacture and markets a diverse range of pharmaceutical formulations, herbal remedies and APIs.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: